Have a personal or library account? Click to login
Current state of angina treatment in the outpatient population and heart rate monitoring survey in Latvia (RELITY LATVIA) Cover

Current state of angina treatment in the outpatient population and heart rate monitoring survey in Latvia (RELITY LATVIA)

Open Access
|Aug 2011

Abstract

The aim of the REALITY Latvia survey was to accumulate information about treated stable angina outpatients regarding their characteristics, heart rate (HR), treatment, and quality of life. Thirty cardiologists were involved with 1-15 patients each. In total, data about 300 patients were obtained. Patients were examined and questioned during one visit. A high HR was defined above 70 beats per minute (bpm), in accordance to recent evidence. Mean HR was 70.3 ± 11.3 bpm and 45% of patients had HR above 70 bpm. The opinion of practitioners regarding HR differed. For example, a HR level within the range 70-80 bpm was perceived by cardiologists as "normal", "borderline high" and "high". The mean target HR that physicians wanted to achieve was 60.1 ± 4.7 bpm. Beta blockers were used in 91% of cases. The more widely used beta blockers were metoprolol (47%) and bisoprolol (35%) in mean daily doses 69.7 ± 30.1 mg and 5.3 ± 2.0 mg, respectively. REALITY Latvia data suggest that, despite wide use of beta blockers, HR control in stable angina patients is insufficient. This is caused by insufficient understanding of HR as a treatment target by physicians and use of beta blockers in suboptimal dosages.

DOI: https://doi.org/10.2478/v10046-011-0004-6 | Journal eISSN: 2255-890X | Journal ISSN: 1407-009X
Language: English
Page range: 194 - 201
Published on: Aug 9, 2011
Published by: Latvian Academy of Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year

© 2011 Inga Balode, Sanda Jēgere, Iveta Mintāle, Inga Narbute, Ilja Zakke, Gustavs Latkovskis, Andrejs Ērglis, published by Latvian Academy of Sciences
This work is licensed under the Creative Commons License.